Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (NCT03652545)
Phase I REsearch on Multi-antigen T Cell Infusion Against Neuro-oncologic Disease
🩺 Plain-English Summary (8th-Grade Level)
This Phase I dose-escalation trial is designed to determine the safety and feasibility of rapidly generated tumor multi-antigen associated specific cytotoxic T lymphocytes (TAA-T) in patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). Pediatric and adult patients who have high-risk CNS tumors known to typically have positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or Survivin) will be eligible. TAA-T will all be generated from patient peripheral blood mononuclear cells (PBMC). Group A patients (DIPG): The first TAA-T dose will be infused any time 14 days or more after completion of radiotherapy. Group B patients (other recurrent/progressive/refractory CNS tumors): The first TAA-T dose will be infused any time 14 days or more after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.
Who can join: Review the eligibility criteria below.
Location: Brain Tumor Institute, Children's National Medical Center — Washington D.C., District of Columbia
Age range: 6 Months to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Brain Tumor Institute, Children's National Medical Center — Washington D.C., District of Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Tumor
- Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound — Toronto, Ontario
- Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study — Memphis, Tennessee
- Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors — Hartford, Connecticut
- Understanding the Late Effects of Surviving a Pediatric Brain Tumor — New York, New York
- Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG — Toronto, Ontario
- Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors. — Miami, Florida
Explore by condition: All Brain Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.